KOSDAQ - Delayed Quote KRW

Komipharm International Co., Ltd. (041960.KQ)

4,175.00 +35.00 (+0.85%)
At close: April 26 at 3:30 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
42,647,034.86
42,647,034.86
39,800,517.85
35,847,403.53
37,160,448.88
Cost of Revenue
29,988,868.25
29,988,868.25
28,341,686.34
24,613,150.95
23,784,216.80
Gross Profit
12,658,166.61
12,658,166.61
11,458,831.51
11,234,252.58
13,376,232.08
Operating Expense
18,931,254.18
18,931,254.18
15,262,614.27
16,524,951.53
15,551,096.82
Operating Income
-6,273,087.57
-6,273,087.57
-3,803,782.76
-5,290,698.95
-2,174,864.74
Net Non Operating Interest Income Expense
-1,873,583.93
-1,873,583.93
-1,988,398.33
-1,516,317.46
-1,384,115.17
Pretax Income
-5,739,453.25
-5,739,453.25
-7,479,698.71
-5,934,355.76
-3,956,597.68
Tax Provision
171,152.19
171,152.19
--
--
--
Net Income Common Stockholders
-3,979,102.61
-3,979,102.61
-6,513,790.27
-4,459,354.10
-2,815,610.66
Basic EPS
-57.00
--
-84.49
-63.60
-39.97
Diluted EPS
-57.00
--
-84.49
-63.60
-39.97
Basic Average Shares
69,808.82
--
77,093.12
70,119.48
70,254.08
Diluted Average Shares
69,808.82
--
77,093.12
70,119.48
70,254.08
Total Operating Income as Reported
-6,273,087.67
-6,273,087.67
-3,803,782.87
-5,290,699.07
-2,174,864.69
Rent Expense Supplemental
9,986.79
9,986.79
7,699.78
4,349.49
--
Total Expenses
48,920,122.43
48,920,122.43
43,604,300.61
41,138,102.48
39,335,313.62
Net Income from Continuing & Discontinued Operation
-3,979,102.61
-3,979,102.61
-6,513,790.27
-4,459,354.10
-2,815,610.66
Normalized Income
-5,253,889.73
-5,253,889.73
-7,246,030.95
-4,764,563.47
-2,958,036.05
Interest Income
678,361.17
678,361.17
227,682.53
140,212.78
165,334.90
Interest Expense
2,551,945.00
2,551,945.00
2,216,081.00
1,656,530.00
1,549,450.07
Net Interest Income
-1,873,583.93
-1,873,583.93
-1,988,398.33
-1,516,317.46
-1,384,115.17
EBIT
-3,187,508.25
-3,187,508.25
-5,263,617.71
-4,277,825.76
-2,407,147.61
EBITDA
341,747.51
341,747.51
-1,437,493.79
-695,364.52
1,332,426.25
Reconciled Cost of Revenue
29,988,868.25
29,988,868.25
28,341,686.34
24,613,150.95
23,784,216.80
Reconciled Depreciation
3,529,255.76
3,529,255.76
3,826,123.92
3,582,461.24
3,739,573.86
Net Income from Continuing Operation Net Minority Interest
-3,979,102.61
-3,979,102.61
-6,513,790.27
-4,459,354.10
-2,815,610.66
Total Unusual Items Excluding Goodwill
1,677,351.47
1,677,351.47
732,240.68
305,209.37
142,425.39
Total Unusual Items
1,677,351.47
1,677,351.47
732,240.68
305,209.37
142,425.39
Normalized EBITDA
-1,335,603.96
-1,335,603.96
-2,169,734.47
-1,000,573.89
1,190,000.86
Tax Rate for Calcs
0.00
0.00
--
--
--
Tax Effect of Unusual Items
402,564.35
402,564.35
--
--
--
12/31/2020 - 10/30/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade